RxDoctor Payments Data

Jillian Dinan

Optometrist · Canandaigua, NYNPI 1316389448

Payments from drug & device makers

$921in general payments, 2019–2025

Across 38 payments — averaging $24.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$229
  • Bausch & Lomb Americas Inc.$187
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$147
  • Amgen$119
  • Sun Pharmaceutical Industries Inc.$78
  • AbbVie$44
  • plus $117 from 4 others

What the payments were for

  • Food & beverage$921100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$921 in reported general payments places this provider in the 60th percentile of 2,743 optometrist providers in New York.

See all optometrist providers in New York

Medicare billing

Part B allowed, 2024
$64,726
Medicare patients
371
Services billed
742

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost40$20,865
RocklatanNetarsudil Mesylat/Latanoprost24$16,355
RestasisCyclosporine20$13,388
XiidraLifitegrast15$12,771
Cyclosporine31$12,675
RhopressaNetarsudil Mesylate21$7,763
Travoprost28$7,082
Latanoprost454$5,921
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat236$5,043
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol21$4,251
SimbrinzaBrinzolamide/Brimonidine Tart21$4,095
Brimonidine Tartrate162$3,226
Dorzolamide Hcl92$2,224
Loteprednol Etabonate18$1,974
Timolol Maleate105$1,804

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis$44$34,25360 claims
Bausch & Lomb Americas Inc.Xiidra$187$12,77115 claims
AlconSimbrinza$229$4,09521 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$147$1,97418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,743 optometrist providers in New York.

Other optometrist in Canandaigua

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →